Solara Active Pharma Sciences reported a 60% year-on-year increase in consolidated profit after tax (PAT) to ₹163 million for the quarter ended June 30, 2026, driven by robust growth in its core Active Pharmaceutical Ingredient (API) business. Revenue from operations rose 20% to ₹3,816 million, while EBITDA grew 10% to ₹635 million. The Board of Directors approved the unaudited standalone and consolidated financial results on July 23, 2026, following a limited review by statutory auditors Deloitte Haskins & Sells LLP. Despite the quarterly profit, the group carries accumulated losses of ₹28,621 million as of June 30, 2026, though management maintains a going concern basis citing adequate working capital facilities and operational cash flows.

Financial Performance Highlights

The company’s strong performance was anchored by its base business, which excludes the commodity Ibuprofen segment. Base business revenues surged 24% to ₹3,077 million, up from ₹2,487 million in the corresponding period of the previous year. This growth offset profitability challenges in the Ibuprofen business, which reported an EBITDA loss of ₹87 million on revenues of ₹765 million. Management is evaluating strategic options for the Ibuprofen unit and expects to finalize next steps by the end of Q2FY27. Consequently, the previously approved demerger of the CRAMS and Polymers business has been placed on hold.

Balance Sheet and Rights Issue Utilization

Solara Active Pharma Sciences significantly improved its balance sheet position, reducing net debt by ₹1,346 million during the quarter to ₹4,795 million. This reduction was achieved through the repayment of ₹1,000 million from rights issue proceeds and ₹346 million from operational cash flows. As of June 30, 2026, the company had raised ₹44,273 million out of the total rights issue size of ₹44,995 million. The proceeds comprise ₹15,748 million received as application money, ₹15,531 million against the first call made on May 6, 2025, and ₹12,994 million against the final call made on May 7, 2026. The unutilized balance is held in bank accounts pending deployment.

The net worth improved to ₹10,419 million as of June 30, 2026, up from ₹8,880 million in March 2026. Management projects net debt to reach approximately ₹4,406 million by March 2027, targeting a net debt-to-EBITDA ratio of around 1.7 times.

What the Numbers Show

The divergence between the base business and the Ibuprofen segment highlights the structural shift in Solara’s revenue mix. While the base business delivered a healthy 23.5% EBITDA margin, supported by regulated markets contributing over 75% of revenues, the Ibuprofen segment continues to drag on overall profitability. The substantial reduction in net debt, coupled with the near-complete closure of the rights issue, provides the company with a stronger liquidity buffer to navigate input cost pressures from geopolitical developments in West Asia. However, the persistent accumulated losses of over ₹28,000 million underscore the long-term capital intensity of the business model, making the successful execution of strategic options for the Ibuprofen unit critical for future margin expansion.

Solara Active Pharma Sciences has laid out a comprehensive multi-year capital expenditure strategy, signalling a focused approach to capacity enhancement and operational continuity. The company has detailed spending plans across FY27, FY28, and FY29, with specific allocations earmarked for debottlenecking and maintenance activities.

Capital Expenditure Plan for FY27

In FY27, Solara Active Pharma Sciences plans to deploy INR 55-60 crores in capital expenditure. The allocation is structured to address both capacity expansion and upkeep of existing infrastructure. The following table outlines the planned spending breakdown for FY27:

The debottlenecking spend of INR 40 crores reflects the company's intent to address capacity constraints within its existing manufacturing setup, while the INR 10-15 crores earmarked for maintenance underscores a commitment to sustaining operational efficiency.

Medium-Term Expenditure Outlook: FY28 and FY29

Looking beyond FY27, Solara Active Pharma Sciences expects annual capital expenditure to moderate to a range of INR 40-50 crores in both FY28 and FY29. This sustained investment trajectory indicates a continued focus on strengthening the company's manufacturing capabilities over the medium term.

Operational Expansion Within 12-18 Months

In addition to its capital expenditure roadmap, Solara Active Pharma Sciences has outlined plans to expand its current operations and initiate new ones within the next 12-18 months. This dual-pronged approach—scaling existing facilities while launching new operations—reflects the company's broader strategy to strengthen its active pharmaceutical ingredients (API) business footprint.

The combination of near-term debottlenecking investments in FY27 and a steady annual capex commitment through FY28 and FY29 positions the company to progressively build on its manufacturing capacity over the coming years.